<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-10939</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0006329</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Immunology</subject><subject>Immunology/Immunity to Infections</subject><subject>Immunology/Immunomodulation</subject><subject>Immunology/Innate Immunity</subject><subject>Immunology/Leukocyte Signaling and Gene Expression</subject></subj-group></article-categories><title-group><article-title>TLR2-Dependent Inhibition of Macrophage Responses to IFN-&#x003b3; Is Mediated by Distinct, Gene-Specific Mechanisms</article-title><alt-title alt-title-type="running-head">Inhibition of Transcription</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Benson</surname><given-names>Sarah A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ernst</surname><given-names>Joel D.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Medicine, Division of Infectious Diseases, New York University School of Medicine, New York, New York, United States of America</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Microbiology, New York University School of Medicine, New York, New York, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Pathology, New York University School of Medicine, New York, New York, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Means</surname><given-names>Terry</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Massachusetts General Hospital/Harvard University, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>joel.ernst@med.nyu.edu</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: SB JE. Performed the experiments: SB. Analyzed the data: SB JE. Wrote the paper: SB JE.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2009</year></pub-date><volume>4</volume><issue>7</issue><elocation-id>e6329</elocation-id><history><date date-type="received"><day>9</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Benson, Ernst. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><p><italic>Mycobacterium tuberculosis</italic> uses multiple mechanisms to avoid elimination by the immune system. We have previously shown that <italic>M. tuberculosis</italic> can inhibit selected macrophage responses to IFN-&#x003b3; through TLR2-dependent and -independent mechanisms. To specifically address the role of TLR2 signaling in mediating this inhibition, we stimulated macrophages with the specific TLR2/1 ligand Pam<sub>3</sub>CSK<sub>4</sub> and assayed responses to IFN-&#x003b3;. Pam<sub>3</sub>CSK<sub>4</sub> stimulation prior to IFN-&#x003b3; inhibited transcription of the unrelated IFN-&#x003b3;-inducible genes, CIITA and CXCL11. Surface expression of MHC class II and secretion of CXCL11 were greatly reduced as well, indicating that the reduction in transcripts had downstream effects. Inhibition of both genes required new protein synthesis. Using chromatin immunoprecipitation, we found that TLR2 stimulation inhibited IFN-&#x003b3;-induced RNA polymerase II binding to the CIITA and CXCL11 promoters. Furthermore, TATA binding protein was unable to bind the TATA box of the CXCL11 promoter, suggesting that assembly of transcriptional machinery was disrupted. However, TLR2 stimulation affected chromatin modifications differently at each of the inhibited promoters. Histone H3 and H4 acetylation was reduced at the CIITA promoter but unaffected at the CXCL11 promoter. In addition, NF-&#x003ba;B signaling was required for inhibition of CXCL11 transcription, but not for inhibition of CIITA. Taken together, these results indicate that TLR2-dependent inhibition of IFN-&#x003b3;-induced gene expression is mediated by distinct, gene-specific mechanisms that disrupt binding of the transcriptional machinery to the promoters.</p></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Macrophages are important mediator cells during the immune response to invading pathogens. They are able to recognize a variety of pathogens through cell surface receptors, including members of the Toll-like receptor (TLR) family <xref ref-type="bibr" rid="pone.0006329-Aderem1">&#x0005b;1&#x0005d;</xref>. Among these receptors, TLR2 and TLR4 specifically recognize bacteria-derived lipopeptides and LPS, respectively. Engagement of TLRs results in activation of MAPK and NF-&#x003ba;B signaling pathways, culminating in the expression of proinflammatory cytokines and antimicrobial effector molecules <xref ref-type="bibr" rid="pone.0006329-Dunne1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Foster1">&#x0005b;3&#x0005d;</xref>, as well as in the induction of apoptosis <xref ref-type="bibr" rid="pone.0006329-Lopez1">&#x0005b;4&#x0005d;</xref>.</p><p>Macrophages also function as effector cells in the adaptive immune response. While macrophages play an important part in controlling infections as part of the innate immune response, full activation of their antimicrobial capacity and antigen presentation function only occurs after stimulation with the Th1 cytokine IFN-&#x003b3; <xref ref-type="bibr" rid="pone.0006329-Mosser1">&#x0005b;5&#x0005d;</xref>. IFN-&#x003b3; is essential for the control of <italic>Mycobacterium tuberculosis</italic><xref ref-type="bibr" rid="pone.0006329-Mogues1">&#x0005b;6&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006329-Flynn2">&#x0005b;9&#x0005d;</xref> and the clearance of other intracellular pathogens <xref ref-type="bibr" rid="pone.0006329-Murray1">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006329-Skerrett1">&#x0005b;13&#x0005d;</xref>.</p><p>IFN-&#x003b3; acts by binding to the heterodimeric IFN-&#x003b3; receptor. Receptor binding and dimerization leads to the recruitment of JAKs 1 and 2 and ultimately to tyrosine and serine phosphorylation of the transcription factor STAT1 <xref ref-type="bibr" rid="pone.0006329-Levy1">&#x0005b;14&#x0005d;</xref>. Phospho-STAT1 dimers then drive gene expression by binding gamma-activated sites (GAS) in the promoters of a large number of genes.</p><p>While exposure to a TLR agonist and IFN-&#x003b3; can have synergistic effects and enhance activation of some IFN-&#x003b3;-induced genes <xref ref-type="bibr" rid="pone.0006329-Kovarik1">&#x0005b;15&#x0005d;</xref>, a number of studies have shown that LPS <xref ref-type="bibr" rid="pone.0006329-Stoiber1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Yao1">&#x0005b;17&#x0005d;</xref>, whole mycobacteria <xref ref-type="bibr" rid="pone.0006329-Kincaid1">&#x0005b;18&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006329-Ting1">&#x0005b;22&#x0005d;</xref>, the mycobacterial lipoglycan phosphatidylinositol mannan <xref ref-type="bibr" rid="pone.0006329-Banaiee1">&#x0005b;23&#x0005d;</xref>, and mycobacterial lipoproteins <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pennini1">&#x0005b;25&#x0005d;</xref> can have inhibitory effects on a subset of IFN-&#x003b3;-induced genes. This appears to be of special relevance in the context of infections with <italic>M. tuberculosis</italic> where, even in the presence of a strong adaptive immune response, clearance of bacteria from the infected tissue is not achieved <xref ref-type="bibr" rid="pone.0006329-Mogues1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Barnes1">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Gomez1">&#x0005b;27&#x0005d;</xref>.</p><p>Although inhibition of IFN-&#x003b3;-induced gene expression by <italic>M. tuberculosis</italic> occurs by both TLR2-dependent and -independent mechanisms in vitro <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref> and in vivo <xref ref-type="bibr" rid="pone.0006329-Kincaid2">&#x0005b;28&#x0005d;</xref>, we focused on the contribution of TLR2 signaling to inhibition in the experiments reported here. Pam<sub>3</sub>CSK<sub>4</sub>, a synthetic triacylated hexapeptide and specific TLR2/1 ligand <xref ref-type="bibr" rid="pone.0006329-Jin1">&#x0005b;29&#x0005d;</xref>, has been found to mimic the inhibitory effects of mycobacterial lipoproteins in macrophages <xref ref-type="bibr" rid="pone.0006329-Banaiee1">&#x0005b;23&#x0005d;</xref>. Inhibition of class II transactivator (CIITA), a gene required for antigen presentation via MHC class II to CD4<sup>&#x0002b;</sup> T cells <xref ref-type="bibr" rid="pone.0006329-Steimle1">&#x0005b;30&#x0005d;</xref>, has been well characterized <xref ref-type="bibr" rid="pone.0006329-Kincaid1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pai1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pennini1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pennini2">&#x0005b;31&#x0005d;</xref>. We wanted to extend these findings and compare inhibition of CIITA with that of CXCL11, another IFN-&#x003b3;-inducible gene that we found to be strongly inhibited by Pam<sub>3</sub>CSK<sub>4</sub> through microarray analysis. CXCL11 is a member of the CXC chemokine family and ligand for CXCR3, which is expressed on activated CD4<sup>&#x0002b;</sup> T cells <xref ref-type="bibr" rid="pone.0006329-Loetscher1">&#x0005b;32&#x0005d;</xref>. CXCL11 acts as a chemoattractant to recruit these cells to the site of inflammation <xref ref-type="bibr" rid="pone.0006329-Cole1">&#x0005b;33&#x0005d;</xref>. Although studied during chronic <italic>M. tuberculosis</italic> infection <xref ref-type="bibr" rid="pone.0006329-Fuller1">&#x0005b;34&#x0005d;</xref>, the role of CXCL11 during early infection is unknown.</p><p>We found that TLR2 inhibition of IFN-&#x003b3;-induced transcription of CXCL11 and CIITA required new protein synthesis, but that inhibition of each of these genes involved distinct downstream mechanisms.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Reagents and antibodies</title><p>(S)-&#x0005b;2,3,-Bis(palmitoyloxy)-(2-<italic>RS</italic>)-propyl&#x0005d;-<italic>N</italic>-palmitoyl-(<italic>R</italic>)-Cys-(<italic>S</italic>)-Ser-(<italic>S</italic>)-Lys<sub>4</sub>-OH, 3HCl (Pam<sub>3</sub>CSK<sub>4</sub>; Calbiochem) was stored at 1 mg/ml in endotoxin-tested water (Invitrogen Life Technologies). Cycloheximide (Calbiochem) was stored at 100 mg/ml (355 mM) in DMSO. Recombinant murine IFN-&#x003b3; was purchased from BD Biosciences. Polyclonal anti-acetyl-histone H3 and H4 antibodies were from Millipore. Antibodies for RNA polymerase II (N-20) and TFIID (TBP) (N-12) were purchased from Santa Cruz Biotechnology.</p></sec><sec id="s2b"><title>Mice</title><p>C57BL/6 mice were purchased from The Jackson Laboratory, BALB/c mice were purchased from Taconic, and TNF&#x003ba;B (TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x0002b;/&#x02212;</sup>) mice were purchased from Riken. All were maintained under specific pathogen-free conditions. All work with animals was approved by the New York University School of Medicine Institutional Animal Care and Use Committee.</p></sec><sec id="s2c"><title>Isolation and culture of bone marrow-derived macrophages</title><p>Bone marrow-derived macrophages (BMDM) were isolated and cultured as previously described <xref ref-type="bibr" rid="pone.0006329-Banaiee1">&#x0005b;23&#x0005d;</xref>. All experiments were done with C57BL/6 BMDM unless otherwise specified.</p></sec><sec id="s2d"><title>RNA harvest and quantitative real-time PCR (qPCR)</title><p>BMDM from BALB/c mice (2&#x000d7;10<sup>6</sup>) were incubated with Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) for 8 h followed by IFN-&#x003b3; (20 ng/ml) for 4, 8, and 12 h. For cycloheximide experiments, BMDM from C57BL/6 mice were pretreated with DMSO or cycloheximide (500 nM) for 1 h, followed by Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) for 8 h followed by IFN-&#x003b3; (20 ng/ml) for 4 h in the continued absence or presence of the inhibitor. For examining NF-&#x003ba;B, BMDM from TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x0002b;/&#x0002b;</sup> and TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x02212;/&#x02212;</sup> mice were treated with Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) for 8 h followed by IFN-&#x003b3; (20 ng/ml) for 4 h. Total RNA was harvested using Qiagen RNeasy columns according to the manufacturer's directions. Genomic DNA contamination was removed by DNase treatment (Ambion). Total RNA yield was determined by nanodrop quantitation and 1 &#x000b5;g was reverse transcribed using the Reverse Transcription System (Promega). The cDNA equivalent of 10 ng (for GAPDH) or 50 ng (for CXCL11, CIITA, and NOS2) of total RNA was analyzed by quantitative PCR using FastStart Universal SYBR Green Master Mix (Roche) on an MJ Research Opticon 2. For quantitation, the relative values were determined by comparing the threshold cycle of each sample to a standard curve consisting of serial dilutions of a positive control cDNA sample and normalized to GAPDH. The following primers were used: CXCL11 sense, <named-content content-type="gene">5&#x02032;-GCA CCT CTT TCA GTC TGT TTC CTG-3&#x02032;</named-content>; CXCL11 antisense, <named-content content-type="gene">5&#x02032;-AGC CAT CCC TAC CAT TCA TTC AC-3&#x02032;</named-content>; CIITA pIV sense, <named-content content-type="gene">5&#x02032;-GAA GTT CAC CAT TGA GCC ATT TAA-3&#x02032;</named-content>; CIITA pIV antisense, <named-content content-type="gene">5&#x02032;-CTG GGT CTG CAC GAG ACG AT-3&#x02032;</named-content>; NOS2 sense, <named-content content-type="gene">5&#x02032;-GTT CTC AGC CCA ACA ATA CAA GA-3&#x02032;</named-content>; NOS2 antisense, <named-content content-type="gene">5&#x02032;-GTG GAC GGG TCG ATG TCA C-3&#x02032;</named-content>; GAPDH sense, <named-content content-type="gene">5&#x02032;-TGT GTC CGT CGT GGA TCT GA-3&#x02032;</named-content>; GAPDH antisense, <named-content content-type="gene">5&#x02032;-CCT GCT TCA CCA CCT TCT TGA-3&#x02032;</named-content>.</p></sec><sec id="s2e"><title>Flow cytometry</title><p>Macrophages (2&#x000d7;10<sup>6</sup>) were plated on non-tissue culture treated plates and treated with Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) for 12&#x02013;15 h, followed by IFN-&#x003b3; (20 ng/ml) for 24 h. Cells were harvested from plates by incubation in PBS containing 5 mM EDTA for 20 min at 4&#x000b0;C, then vigorous pipetting. Cells were stained with Alexa 647-conjugated anti-mouse I-A/I-E (Biolegend), washed, and resuspended in ice-cold FACS buffer (PBS, 0.1&#x00025; sodium azide, 1&#x00025; FCS, 500 &#x000b5;M EDTA). Cells were analyzed for MHC class II surface expression using a FACSCalibur (30,000 total events gated by forward and side scatter; BD Biosciences).</p></sec><sec id="s2f"><title>ELISA</title><p>Since the CXCL11 gene in C57BL/6 mice contains a point mutation that results in the lack of CXCL11 secretion <xref ref-type="bibr" rid="pone.0006329-Sierro1">&#x0005b;35&#x0005d;</xref>, BMDM from BALB/c mice were treated with Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) for 8 h, followed by IFN-&#x003b3; (20 ng/ml) for 4, 8, and 12 h. Culture supernatants were harvested and assayed for murine CXCL11 by ELISA according to the manufacturer's directions (R &#x00026; D Systems). Samples were used neat or diluted 1&#x02236;10 or 1&#x02236;50 to allow detection within the range of the assay. Results were quantitated using an EL<sub>x</sub>800<sub>UV</sub> spectrophotometer (Bio-Tek Instruments).</p></sec><sec id="s2g"><title>Chromatin immunoprecipitation (ChIP)</title><p>8&#x02212;10&#x000d7;10<sup>6</sup> macrophages were treated with Pam<sub>3</sub>CSK<sub>4</sub> (10 ng/ml) for 8&#x02013;9 h, followed by IFN-&#x003b3; (20 ng/ml) for 4, 8, and 12 h (for PolII and TBP binding) or 1, 2, 4, and 8 h (for histone acetylation). Cells were crosslinked by adding 1&#x00025; formaldehyde for 10 min at 37&#x000b0;C, followed by addition of glycine (125 mM) for 5 min at room temperature. Cells were washed twice with ice-cold PBS and scraped in PBS containing protease inhibitors (Complete Mini, Roche). Fixed cells were pelleted and snap-frozen in liquid nitrogen. Samples were processed using the ChIP assay kit from Millipore (17&#x02013;295). Cell pellets were thawed, resuspended in SDS lysis buffer, and lysed on ice for 10 min. Chromatin was fragmented using a Branson Digital Sonifier 250 (6 rounds at 20&#x00025; amplitude for 40 s each round (0.5 s pulse, 1 s break)). One-third of the fragmented chromatin was diluted five-fold in ChIP dilution buffer. 1&#x00025; of each sample was set aside as input DNA. Chromatin was immunoprecipitated overnight with anti-RNA polymerase II (10 &#x000b5;g), anti-TFIID (10 &#x000b5;g), or anti-acetylated histone H3 (5 &#x000b5;g) or H4 (4 &#x000b5;g) antibodies; the specificity of binding was determined using controls in which the primary antibody was omitted. Chromatin-antibody complexes were captured by incubation with protein A agarose beads for 1 h at 4&#x000b0;C, then chromatin-antibody-bead complexes were washed for 5 min at 4&#x000b0;C with 1 ml of each buffer in the following order: low salt immune complex wash buffer, high salt immune complex wash buffer, LiCl immune complex wash buffer, and TE (as described in the manufacturer's protocol). Chromatin was released from the beads with elution buffer (1&#x00025; SDS, 0.1 M NaHCO<sub>3</sub>), and crosslinking was reversed by incubating input and sample chromatin in 0.2 M NaCl for 4 h at 65&#x000b0;C. Sample chromatin was incubated with proteinase K for 1 h at 45&#x000b0;C and ethanol-precipitated, then sample and input chromatin were diluted five-fold in PB buffer and purified with QiaQuick columns according to the manufacturer's protocol (Qiagen). Purified sample and input DNA was eluted with 50 &#x000b5;l EB buffer. 2.5 &#x000b5;l of eluted DNA were assayed by qPCR using primers specific for the promoter region of the assayed gene and genomic DNA as standard. ChIP output was normalized to the amount of input DNA. The resulting values for each gene were normalized using their corresponding GAPDH values. Fold enrichment is expressed in relation to the value determined for the untreated sample value. The primers used are listed in <xref ref-type="table" rid="pone-0006329-t001">Table 1</xref>.</p><table-wrap id="pone-0006329-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.t001</object-id><label>Table 1</label><caption><title>Primers used for ChIPs.</title></caption><alternatives><graphic id="pone-0006329-t001-1" xlink:href="pone.0006329.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Primer name</td><td align="left" rowspan="1" colspan="1">Sequence (5&#x02032; to 3&#x02032;)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CXCL11_HISF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCT GCC CAG AAT CCC TAC AC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL11_HISR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGA AGC CAC TGG AAG GTG AA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">GAPDH_HISF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGT CCA AAG AGA GGG AGG AG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">GAPDH_HISR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGC TAC GTG CAC CCG TAA AG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CIITA_HISF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGC AAA CTT GGG TTG CAT GT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CIITA_HISR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCC TGG CAG CTA TCT CAC AA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">NOS2_HISF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAC TAT TCT GCC CAA GCT GAC TTA C</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">NOS2_HISR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAA TAT TCC AAC ACG CCC AGG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL11_POLF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACT GCC TGA AGA TTG CTG GT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL11_POLR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ATA TTG CAG CCA GGG CTA TG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">GAPDH_POLF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCG CAT CTT CTT GTG CAG T</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">GAPDH_POLR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCC CTA GAC CCG TAC AGT GC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CIITA_POLF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GAT AGC TGC CAG GAG ACT GC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CIITA_POLR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CAA ACG GGA TCT TGG AGA CA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">NOS2_POLF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCC TTT GGG AAC AGT TAT GC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">NOS2_POLR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCA AGG TGG CTG AGA AGT TT</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL11_TBPF</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCT GAG TGC TTT CAC CTT CC</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1">CXCL11_TBPR</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGC TGA ACC TGA GGA GTC TG</named-content></td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>TLR2 stimulation inhibits IFN-&#x003b3;-induced transcription of CXCL11 and CIITA, but not NOS2</title><p>In the context of initial infection with <italic>M. tuberculosis</italic>, lung macrophages are likely to encounter the bacteria before being stimulated by IFN-&#x003b3;. Therefore, we studied the effects of TLR2 stimulation by Pam<sub>3</sub>CSK<sub>4</sub> prior to stimulation of macrophages with IFN-&#x003b3;. We first analyzed the kinetics of TLR2-initiated inhibition of IFN-&#x003b3; induction of CXCL11 and CIITA. Bone marrow-derived macrophages (BMDM) were treated with Pam<sub>3</sub>CSK<sub>4</sub> for 8 h then stimulated with IFN-&#x003b3; for 4, 8, and 12 h. Although CIITA and CXCL11 were both induced by IFN-&#x003b3;, the kinetics of their induction differed. CXCL11 mRNA levels peaked after 4 h of IFN-&#x003b3; stimulation whereas CIITA mRNA peaked after 12 h (<xref ref-type="fig" rid="pone-0006329-g001">Figs. 1A and B</xref>). Transcription of both CXCL11 and CIITA was fully inhibited in cells previously exposed to Pam<sub>3</sub>CSK<sub>4</sub>, regardless of the length of IFN-&#x003b3; stimulation. As a control, we examined transcription of NOS2, an IFN-&#x003b3;-inducible gene that has been found not to be inhibited by <italic>M. tuberculosis</italic> or mycobacterial lipoproteins <xref ref-type="bibr" rid="pone.0006329-Pai2">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>. We found that Pam<sub>3</sub>CSK<sub>4</sub> treatment prior to IFN-&#x003b3; stimulation enhanced transcription of NOS2 in macrophages (<xref ref-type="fig" rid="pone-0006329-g001">Fig. 1C</xref>). These data show that TLR2 stimulation affects IFN-&#x003b3;-induced transcription in a gene-specific manner.</p><fig id="pone-0006329-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.g001</object-id><label>Figure 1</label><caption><title>TLR2 stimulation inhibits IFN-&#x003b3;-induced transcription of a subset of genes.</title><p>BALB/c BMDM were treated with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 8 h, and then 20 ng/ml IFN-&#x003b3; for 4, 8, and 12 h. Total RNA was harvested, reverse transcribed, and CXCL11 (A), CIITA (B), and NOS2 (C) expression analyzed by quantitative real-time PCR (qPCR). All values were normalized to GAPDH. Results are shown as fold induction compared to untreated sample without Pam<sub>3</sub>CSK<sub>4</sub> or IFN-&#x003b3;. &#x0002a;, p&#x0003c;0.01, &#x0002a;&#x0002a;, p&#x0003c;0.05 comparing IFN-&#x003b3; alone samples with those treated with Pam<sub>3</sub>CSK<sub>4</sub> prior to IFN-&#x003b3; (as determined by two-tailed t test). Results in (A) are expressed as means&#x000b1;SEM of three independent experiments. Results in (B) and (C) are representative of three independent experiments. Similar results were obtained with C57BL/6 BMDM.</p></caption><graphic xlink:href="pone.0006329.g001"/></fig></sec><sec id="s3b"><title>TLR2 stimulation inhibits CXCL11 protein production and MHC class II surface expression</title><p>Since transcription of CXCL11 and CIITA was significantly reduced in TLR2 stimulated macrophages, we determined whether inhibition was reflected by reduction of the protein products of these genes. To examine the effect on CXCL11, we treated BALB/c BMDM with Pam<sub>3</sub>CSK<sub>4</sub> for 8 h followed by IFN-&#x003b3; for 4, 8, and 12 h. Culture supernatants were harvested and assayed for CXCL11 by ELISA. Stimulation with IFN-&#x003b3; resulted in secretion of CXCL11 after 8 and 12 h of treatment (<xref ref-type="fig" rid="pone-0006329-g002">Fig. 2A</xref>). However, prior TLR2 stimulation inhibited IFN-&#x003b3;-induced CXCL11 protein levels by over 80&#x00025; at both of these time points.</p><fig id="pone-0006329-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.g002</object-id><label>Figure 2</label><caption><title>TLR2-mediated inhibition of IFN-&#x003b3; induction of CXCL11 and CIITA decreases expression of protein products.</title><p>A. BALB/c BMDM were treated with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 8 h followed by 20 ng/ml IFN-&#x003b3; for 4, 8, and 12 h. Culture supernatants were collected and assayed for CXCL11 protein by ELISA. &#x0002a;, p&#x0003c;0.01, &#x0002a;&#x0002a;, p&#x0003c;0.05 comparing IFN-&#x003b3; alone with Pam<sub>3</sub>CSK<sub>4</sub> and IFN-&#x003b3; treated samples (as determined by two-tailed t-test). B and C. BMDM were treated with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 12&#x02013;15 h prior to stimulation with 20 ng/ml IFN-&#x003b3; for 24 h. Cells were stained with Alexa 647-conjugated anti-mouse I-A/I-E and analyzed by flow cytometry. Data shown are fluorescence intensity vs. cell number (B) and mean I-A/I-E fluorescence (C). Results are expressed as means&#x000b1;SEM from two independent experiments (A) and are representative of at least five independent experiments (B and C).</p></caption><graphic xlink:href="pone.0006329.g002"/></fig><p>To examine the downstream effect of TLR2 stimulation on CIITA, we measured surface expression of MHC class II, whose expression is regulated by, and depends on, CIITA. BMDM were treated with Pam<sub>3</sub>CSK<sub>4</sub> for 12&#x02013;15 h then stimulated with IFN-&#x003b3; for 24 h (the minimal time needed for increased MHC class II surface expression). IFN-&#x003b3; stimulation alone caused an eleven-fold increase of MHC class II on the cell surface (<xref ref-type="fig" rid="pone-0006329-g002">Fig. 2B</xref>). However, Pam<sub>3</sub>CSK<sub>4</sub> treatment prior to IFN-&#x003b3; inhibited this upregulation by 73&#x00025;, as assessed by mean fluorescent intensity (<xref ref-type="fig" rid="pone-0006329-g002">Fig. 2C</xref>). Pam<sub>3</sub>CSK<sub>4</sub> alone (without IFN-&#x003b3;) had no effect on surface MHC class II levels. These results indicate that TLR2-mediated inhibition of CXCL11 and CIITA transcription has downstream consequences at the protein level.</p></sec><sec id="s3c"><title>TLR2-mediated inhibition of CXCL11 and CIITA requires new protein synthesis</title><p>We have previously shown that <italic>M. tuberculosis</italic>-mediated inhibition of CIITA induction by IFN-&#x003b3; requires new protein synthesis <xref ref-type="bibr" rid="pone.0006329-Banaiee1">&#x0005b;23&#x0005d;</xref>. We extended these findings and examined the effect of cycloheximide, a pharmacological inhibitor of protein synthesis, on induction of CXCL11, CIITA, and NOS2 mRNA by IFN-&#x003b3; in TLR2 stimulated macrophages. In control samples, TLR2 stimulation prior to IFN-&#x003b3; inhibited CXCL11 and CIITA induction, but enhanced NOS2 induction, as previously seen. However, treatment with cycloheximide fully reversed inhibition of CXCL11 and CIITA and further enhanced NOS2 expression (<xref ref-type="fig" rid="pone-0006329-g003">Fig. 3</xref>). These results indicate that TLR2 stimulation induces production of one or more proteins that are required for inhibition of macrophage gene expression in response to IFN-&#x003b3;. Cycloheximide treatment also greatly enhanced expression of all three genes, with the strongest effect on CXCL11, presumably due to the lack of a negative regulatory protein.</p><fig id="pone-0006329-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.g003</object-id><label>Figure 3</label><caption><title>New protein synthesis is required for inhibition of CIITA and CXCL11.</title><p>BMDM were pretreated with 500 nM cycloheximide or DMSO for 1 h prior to treatment with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 8 h followed by 20 ng/ml IFN-&#x003b3; for 4 h in the continued presence or absence of inhibitor. Total RNA was harvested after IFN-&#x003b3; stimulation. CXCL11 (A), CIITA (B), and NOS2 (C) expression was assayed by qPCR and normalized to GAPDH and untreated samples. The concentration of cycloheximide used inhibited TNF production (as a measure of protein synthesis) by over 90&#x00025; with minimal cell death. Statistical significance between IFN-&#x003b3; alone samples and those treated with Pam<sub>3</sub>CSK<sub>4</sub> prior to IFN&#x003b3; was determined by two-tailed t-test.</p></caption><graphic xlink:href="pone.0006329.g003"/></fig></sec><sec id="s3d"><title>TLR2 stimulation prevents RNA polymerase II from binding the CXCL11 and CIITA promoters</title><p>To further characterize the mechanism of inhibition of transcriptional responses to IFN-&#x003b3; by prior TLR2 stimulation, we determined whether RNA polymerase II (PolII) binds the promoters of the affected genes. We treated BMDM with Pam<sub>3</sub>CSK<sub>4</sub> for 8 h then stimulated with IFN-&#x003b3; for 4 h, followed by chromatin immunoprecipitation (ChIP) to assay binding of PolII to the CXCL11, CIITA, and NOS2 promoters. Primers that specifically amplified regions flanking the transcriptional start site of each gene were designed to detect initial binding of PolII to the promoters. IFN-&#x003b3; stimulation induced binding of PolII to the CXCL11 and CIITA promoters, as indicated by a three-fold increase in pulldown of promoter fragments of these genes (<xref ref-type="fig" rid="pone-0006329-g004">Fig. 4A</xref>). However, stimulation of TLR2 prior to IFN-&#x003b3; inhibited binding of PolII by 66&#x00025; (CXCL11) and 76&#x00025; (CIITA) compared with IFN-&#x003b3; alone. The effect of TLR2 stimulation was not merely to delay IFN-&#x003b3;-stimulated PolII binding at these promoters, as similar inhibition of binding was seen after 8 and 12 h of IFN-&#x003b3; stimulation (data not shown). As a control, we assayed PolII binding at the NOS2 promoter, since TLR2 stimulation did not decrease NOS2 mRNA induction by IFN-&#x003b3; (<xref ref-type="fig" rid="pone-0006329-g001">Fig. 1C</xref>). IFN-&#x003b3; stimulation alone caused a two-fold increase in binding and prior Pam<sub>3</sub>CSK<sub>4</sub> treatment resulted in a further increase in binding (<xref ref-type="fig" rid="pone-0006329-g004">Fig. 4A</xref>). This was similar to the effect observed at the level of transcription (<xref ref-type="fig" rid="pone-0006329-g001">Fig. 1C</xref>). These results indicate that TLR2 stimulation prevents PolII from binding to the CXCL11 and CIITA promoters, but does not affect binding to the NOS2 promoter. The effect of TLR2 stimulation on transcription of IFN-&#x003b3;-responsive genes correlates with PolII binding at the respective promoters.</p><fig id="pone-0006329-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.g004</object-id><label>Figure 4</label><caption><title>TLR2 stimulation prevents binding of general transcriptional machinery to the CIITA and CXCL11 promoters.</title><p>BMDM were treated with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 8&#x02013;9 h, then 20 ng/ml IFN-&#x003b3; for 4 h. Cross-linked DNA was sheared and immunoprecipitated with anti-PolII (A) or anti-TBP (B) antibodies. Precipitated and input DNA for each sample were assayed by qPCR with primers specific for the transcriptional start site in the promoters of CXCL11, CIITA, and NOS2 (A) or the TATA box of the CXCL11 promoter (B). All values were normalized to GAPDH. Results are expressed as fold increase over untreated controls and are the mean of triplicate samples&#x000b1;SD. Statistical significance between IFN-&#x003b3; alone samples and Pam<sub>3</sub>CSK<sub>4</sub> prior to IFN-&#x003b3; treated samples was determined by two-tailed t-test. Results are representative of at least two independent experiments.</p></caption><graphic xlink:href="pone.0006329.g004"/></fig></sec><sec id="s3e"><title>TLR2 stimulation prevents binding of TBP to the CXCL11 promoter</title><p>Since we found that TLR2 stimulation prevents PolII from binding the CXCL11 and CIITA promoters, we determined whether another member of the general transcriptional machinery was similarly affected. We examined the ability of TATA binding protein (TBP) to bind the TATA box in the CXCL11 promoter following Pam<sub>3</sub>CSK<sub>4</sub> and IFN-&#x003b3; stimulation. The CIITA promoter lacks a TATA box (our unpublished observation), so we did not include it in our experiments. IFN-&#x003b3; stimulation resulted in a five to seven-fold increase in TBP binding to the CXCL11 promoter after 4, 8, and 12 h (<xref ref-type="fig" rid="pone-0006329-g004">Fig. 4B</xref> and data not shown). However, TLR2 stimulation prior to IFN-&#x003b3; decreased TBP binding to the CXCL11 promoter by 65&#x00025;. This suggests that the lack of transcription is not due to a deficiency in PolII binding alone, but that prolonged TLR2 signaling also inhibits binding of other members of the general transcriptional machinery.</p></sec><sec id="s3f"><title>TLR2 signaling inhibits histone acetylation at the CIITA promoter, but not at the CXCL11 promoter</title><p>Transcriptional activity is usually associated with increased acetylation of histones H3 and H4 in the promoter region of transcribed genes <xref ref-type="bibr" rid="pone.0006329-Strahl1">&#x0005b;36&#x0005d;</xref>, and TLR2 stimulation by the mycobacterial lipoprotein LpqH inhibits acetylation of histones H3 and H4 at the CIITA promoter after 4 h of IFN-&#x003b3; stimulation in macrophages <xref ref-type="bibr" rid="pone.0006329-Pennini1">&#x0005b;25&#x0005d;</xref>. We extended these findings by examining earlier IFN-&#x003b3; time points and by determining whether TLR2 stimulation also inhibited histone acetylation at the CXCL11 promoter. BMDM were treated with Pam<sub>3</sub>CSK<sub>4</sub> for 8 h followed by IFN-&#x003b3; for 1, 2, 4, and 8 h. ChIPs were then performed using antibodies against either acetylated histone H3 or acetylated histone H4. At the CXCL11 promoter, we observed a rapid increase in acetylation of both histones after 1 h of IFN-&#x003b3; stimulation, which persisted for as long as IFN-&#x003b3; was present (<xref ref-type="fig" rid="pone-0006329-g005">Figs. 5A and D</xref>). TLR2 stimulation prior to IFN-&#x003b3; did not inhibit histone acetylation at the CXCL11 promoter at any time point after IFN-&#x003b3; stimulation. In contrast, TLR2 stimulation significantly inhibited histone H3 and H4 acetylation at the CIITA promoter by 35&#x02013;63&#x00025; at all IFN-&#x003b3; time points (<xref ref-type="fig" rid="pone-0006329-g005">Figs. 5B and E</xref>). For comparison, we also examined histone acetylation at the NOS2 promoter. TLR2 stimulation prior to IFN-&#x003b3; resulted in an increase of histone acetylation over IFN-&#x003b3; stimulation alone (<xref ref-type="fig" rid="pone-0006329-g005">Figs. 5C and F</xref>). These data indicate that TLR2-mediated inhibition of IFN-&#x003b3; induction of CIITA and CXCL11 occurs by at least two distinct mechanisms, one that affects histone acetylation and one that does not.</p><fig id="pone-0006329-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.g005</object-id><label>Figure 5</label><caption><title>TLR2 stimulation inhibits histone acetylation at the CIITA promoter, but not the CXCL11 promoter.</title><p>BMDM were treated with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 8 h prior to stimulation with 20 ng/ml IFN-&#x003b3; for 1, 2, 4, and 8 h. Cross-linked, sheared DNA was immunoprecipitated with antibodies against either acetylated histone H3 (A, B, C) or H4 (D, E, F). Precipitates were analyzed by qPCR using primers specific for the CXCL11 (A, D), CIITA (B, E), and NOS2 (C, F) promoters. Values were normalized to GAPDH and untreated controls and are the mean of triplicate samples&#x000b1;SD. &#x0002a;, p&#x0003c;0.01 comparing IFN-&#x003b3; alone with Pam<sub>3</sub>CSK<sub>4</sub> prior to IFN-&#x003b3; treated samples (as determined by two-tailed t-test). Results are representative of two independent experiments.</p></caption><graphic xlink:href="pone.0006329.g005"/></fig></sec><sec id="s3g"><title>NF-&#x003ba;B is required for TLR2-mediated inhibition of CXCL11, but not CIITA, transcription</title><p>Transcriptional responses to TLR2 activation are largely mediated by the transcription factor NF-&#x003ba;B, a heterodimer commonly consisting of the RelA and p50 subunits. RelA deficiency is embryonic lethal but can be rescued by deletion of TNF <xref ref-type="bibr" rid="pone.0006329-Beg1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Doi1">&#x0005b;38&#x0005d;</xref>. We examined the role of NF-&#x003ba;B in TLR2-mediated inhibition of responses to IFN-&#x003b3; using macrophages from TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x02212;/&#x02212;</sup> and TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x0002b;/&#x0002b;</sup> mice. BMDM were treated with Pam<sub>3</sub>CSK<sub>4</sub> for 8 h followed by IFN-&#x003b3; for 4 h. TLR2 stimulation prior to IFN-&#x003b3; inhibited induction of CXCL11 and CIITA in RelA<sup>&#x0002b;/&#x0002b;</sup> macrophages (<xref ref-type="fig" rid="pone-0006329-g006">Figs. 6A and B</xref>). In RelA<sup>&#x02212;/&#x02212;</sup> macrophages, CXCL11 induction by IFN-&#x003b3; was fully restored despite prior TLR2 stimulation (<xref ref-type="fig" rid="pone-0006329-g006">Fig. 6A</xref>). However, CIITA induction was still significantly reduced in these cells (<xref ref-type="fig" rid="pone-0006329-g006">Fig. 6B</xref>). TNF deficiency did not affect transcriptional responses of CXCL11 or CIITA, as results with TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x0002b;/&#x0002b;</sup> macrophages were similar to C57BL/6 macrophages (data not shown). However, lack of TNF did result in lower NOS2 expression that was further decreased in RelA<sup>&#x02212;/&#x02212;</sup> macrophages (<xref ref-type="fig" rid="pone-0006329-g006">Fig. 6C</xref>). These data provide further support that CXCL11 and CIITA are differentially regulated upon TLR2 stimulation. Inhibition of CXCL11 induction requires NF-&#x003ba;B whereas inhibition of CIITA does not.</p><fig id="pone-0006329-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0006329.g006</object-id><label>Figure 6</label><caption><title>IFN-&#x003b3;-induced transcription of CXCL11, but not CIITA, is restored in TLR2 stimulated RelA<sup>&#x02212;/&#x02212;</sup> macrophages.</title><p>BMDM from TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x0002b;/&#x0002b;</sup> and TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x02212;/&#x02212;</sup> mice were treated with 10 ng/ml Pam<sub>3</sub>CSK<sub>4</sub> for 8 h followed by 20 ng/ml IFN-&#x003b3; for 4 h. Total RNA was harvested, reverse transcribed, and CXCL11 (A), CIITA (B), and NOS2 (C) expression analyzed by qPCR. All values were normalized to GAPDH and shown as fold induction compared to untreated samples without Pam<sub>3</sub>CSK<sub>4</sub> or IFN-&#x003b3;. Statistical significance was determined by two-tailed t-test between IFN-&#x003b3; alone with Pam<sub>3</sub>CSK<sub>4</sub> prior to IFN-&#x003b3; samples. C57BL/6 BMDM showed similar results to those obtained with TNF<sup>&#x02212;/&#x02212;</sup>/RelA<sup>&#x0002b;/&#x0002b;</sup> BMDM.</p></caption><graphic xlink:href="pone.0006329.g006"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p><italic>M. tuberculosis</italic> survives in macrophages, even when they are stimulated with IFN-&#x003b3; <xref ref-type="bibr" rid="pone.0006329-Douvas1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Rook1">&#x0005b;40&#x0005d;</xref>. We and others have found that <italic>M. tuberculosis</italic> blocks selected macrophage responses to IFN-&#x003b3; by inhibiting transcription of a subset of IFN-&#x003b3;-inducible genes <xref ref-type="bibr" rid="pone.0006329-Kincaid1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pai1">&#x0005b;20&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006329-Ting1">&#x0005b;22&#x0005d;</xref>. At least two proximal mechanisms are involved. One is initiated by mycobacterial peptidoglycan in a TLR2- and MyD88-independent manner <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>, while the other requires TLR2 and MyD88 and is initiated by lipoproteins and phosphatidylinositol mannan <xref ref-type="bibr" rid="pone.0006329-Banaiee1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>. In the experiments presented here, we examined the mechanisms downstream of TLR2 in mediating this inhibition, by using the specific TLR2/1 agonist Pam<sub>3</sub>CSK<sub>4</sub>.</p><p>This work expands on previous studies that examined inhibition of CIITA transcription <xref ref-type="bibr" rid="pone.0006329-Kincaid1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pai1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pennini1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Pennini2">&#x0005b;31&#x0005d;</xref>, by comparing the kinetics of inhibition of CIITA with that of CXCL11, an unrelated IFN-&#x003b3;-inducible gene, as well as with NOS2, an IFN-&#x003b3;-inducible gene that is not inhibited by <italic>M. tuberculosis</italic><xref ref-type="bibr" rid="pone.0006329-Pai2">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Fortune1">&#x0005b;24&#x0005d;</xref>. We found that TLR2 stimulation inhibited IFN-&#x003b3;-induced transcription of CIITA and CXCL11 to similar levels over a time course of IFN-&#x003b3; stimulation (<xref ref-type="fig" rid="pone-0006329-g001">Figs. 1A and B</xref>), indicating that macrophages are unable to recover the ability to respond to IFN-&#x003b3;, regardless of the length of stimulation. This reduction in transcription resulted in decreased CXCL11 secretion and decreased MHC class II on the macrophage surface (<xref ref-type="fig" rid="pone-0006329-g002">Fig. 2</xref>). However, TLR2 stimulation resulted in an increase in NOS2 mRNA (<xref ref-type="fig" rid="pone-0006329-g001">Fig. 1C</xref>), indicating that TLR2-mediated transcriptional inhibition is gene specific, and therefore not mediated by inhibition of a proximal signaling step such as STAT1 activation.</p><p>One of the initial steps in transcription initiation is acetylation of lysine residues within the N-terminal tails of core histones. This decreases their affinity for DNA, allowing a more permissive chromatin structure for transcription factors and other proteins to bind to DNA <xref ref-type="bibr" rid="pone.0006329-Lee1">&#x0005b;41&#x0005d;</xref>. This process is tightly controlled by two counteracting enzymatic activities: the histone deacetylases (HDACs) and the histone acetyltransferases (HATs). HDACs repress transcription by removing acetyl groups whereas HATs acetylate critical lysines.</p><p>Mammalian HDACs fall into three classes (I, II, and III) based on sequence homology to yeast HDACs <xref ref-type="bibr" rid="pone.0006329-Sengupta1">&#x0005b;42&#x0005d;</xref>. Class II and III HDACs are expressed in a limited number of tissues. However, HDACs 1 and 2 (of class I) appear to be constitutively expressed <xref ref-type="bibr" rid="pone.0006329-Wang1">&#x0005b;43&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0006329-Ito1">&#x0005b;47&#x0005d;</xref>. Therefore, their activity must be tightly regulated. They are the enzymatically active components of multi-protein complexes, which include DNA binding proteins and corepressors. These complexes target the HDACs to the promoters of genes by interactions with sequence-specific transcription factors, leading to transcriptional repression of select genes. HDACs require complex formation for enzymatic activity, as most purified recombinant HDACs are inactive <xref ref-type="bibr" rid="pone.0006329-Hu1">&#x0005b;48&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Lee2">&#x0005b;49&#x0005d;</xref>. In addition to regulation by protein-protein interactions, HDACs can be post-translationally modified. Casein kinase 2 (CK2), a ubiquitously expressed protein kinase, has been identified as a key regulator of class I HDACs <xref ref-type="bibr" rid="pone.0006329-Pflum1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Tsai1">&#x0005b;51&#x0005d;</xref>. CK2 activity is induced by a number of stimuli including IFN-&#x003b3; and the TLR4 ligand LPS <xref ref-type="bibr" rid="pone.0006329-Singh1">&#x0005b;52&#x0005d;</xref>. CK2 phosphorylation of S421/S422 and S423/S424 at the C-terminal region of HDACs 1 and 2, respectively, is important for complex formation and enzymatic activity. Although more light is being shed on how HDAC activity is regulated, many of the signaling pathways involved remain to be elucidated.</p><p>HATs are a diverse group of enzymes that regulate transcription by rendering the chromatin more accessible via acetylation of histone tails. Gene transcription in response to IFN-&#x003b3; involves CREB binding protein (CBP) and/or p300, coactivators that have HAT activity <xref ref-type="bibr" rid="pone.0006329-Kalkhove1">&#x0005b;53&#x0005d;</xref>. Following IFN-&#x003b3; stimulation, phosphorylated STAT1 associates with CBP/p300, which is thought to facilitate contact with transcriptional machinery at the promoter regions of IFN-&#x003b3;-inducible genes <xref ref-type="bibr" rid="pone.0006329-Zhang1">&#x0005b;54&#x0005d;</xref>. Similar to HDACs, the HAT activity of CBP and p300 is tightly regulated via interactions with other proteins as well as by phosphorylation by a number of kinases. Phosphorylation by p42/p44 MAPK, CDK2, protein kinase A, and IKK&#x003b1; upregulate HAT activity <xref ref-type="bibr" rid="pone.0006329-Kalkhove1">&#x0005b;53&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Huang1">&#x0005b;55&#x0005d;</xref> whereas phosphorylation by protein kinase C&#x003b4; reduces HAT activity <xref ref-type="bibr" rid="pone.0006329-Yuan1">&#x0005b;56&#x0005d;</xref>.</p><p>Transcriptional repressors also regulate gene expression. General transcriptional repression occurs when a repressor sequesters or modifies a member of the general transcriptional machinery or PolII itself <xref ref-type="bibr" rid="pone.0006329-Gaston1">&#x0005b;57&#x0005d;</xref>. Expression of all genes transcribed by PolII will then be inhibited. Gene-specific repression occurs when a repressor targets a specific coactivator or interacts in a promoter-specific manner with members of the general transcriptional machinery or PolII. Therefore, only a subset of genes will be inhibited.</p><p>Previously published data suggest that gene-specific repressors may contribute to TLR2-initiated inhibition of transcriptional responses to IFN-&#x003b3; <xref ref-type="bibr" rid="pone.0006329-Pennini2">&#x0005b;31&#x0005d;</xref>. The mycobacterial lipoprotein and TLR2 agonist LpqH induces expression of the transcription factor C/EBP&#x003b2;, which can act as a transcriptional activator or repressor, depending on the promoter and stimulus. This increased expression correlated with inhibition of IFN-&#x003b3;-induced CIITA transcription, and macrophages stimulated with LpqH and IFN-&#x003b3; exhibited increased C/EBP&#x003b2; binding to the CIITA promoter. The NOS2 promoter also has a C/EBP&#x003b2; binding site that is involved in gene induction in response to TLR and IFN-&#x003b3; stimulation <xref ref-type="bibr" rid="pone.0006329-Gupta1">&#x0005b;58&#x0005d;</xref>. The CXCL11 promoter has two potential C/EBP&#x003b2; binding sites from &#x02212;52 to &#x02212;44 (<named-content content-type="gene">TGCCTGAAG</named-content>) and from &#x02212;24 to &#x02212;16 (<named-content content-type="gene">TCCTCAGAC</named-content>), although the functionality of these sites remains to be determined. It is therefore possible that C/EBP&#x003b2; or a related protein may contribute to negative regulation of IFN-&#x003b3;-induction of both CIITA and CXCL11. However, C/EBP&#x003b2;<sup>&#x02212;/&#x02212;</sup> macrophages were found to remain sensitive to LpqH-mediated transcriptional inhibition of CIITA <xref ref-type="bibr" rid="pone.0006329-Pennini2">&#x0005b;31&#x0005d;</xref>, suggesting that additional factors are involved. One such factor may be C/EBP&#x003b4;, whose expression is induced by TLR4 stimulation and has been shown to regulate genes involved in the innate immune response as part of a circuit with other transcription factors <xref ref-type="bibr" rid="pone.0006329-Litvak1">&#x0005b;59&#x0005d;</xref>. TLR2 stimulation also induces C/EBP&#x003b4; expression and binding to the CIITA promoter <xref ref-type="bibr" rid="pone.0006329-Pennini2">&#x0005b;31&#x0005d;</xref>. However, the potential inhibitory function of C/EBP&#x003b4; on IFN-&#x003b3;-induced transcription needs to be explored.</p><p>We attempted to identify other potential transcription factor binding sites that might be responsible for TLR2-mediated inhibition by comparing the promoter sequences of several IFN-&#x003b3;-inducible, Pam<sub>3</sub>CSK<sub>4</sub>-inhibited genes. Computer-based comparison of these promoter sequences with those from a control group of unaffected, IFN-&#x003b3;-inducible genes did not yield an over-represented transcription factor binding motif, indicating that more than one signaling pathway is involved, or that inhibition is mediated by one or proteins that do not bind promoter elements directly (data not shown).</p><p>However, when specifically examining the CXCL11 and CIITA promoters, we found that CXCL11 has an NF-&#x003ba;B binding site at &#x02212;68 to &#x02212;59 (<named-content content-type="gene">GGGGAATTCC</named-content>) that is missing in CIITA. Further investigation of the role of NF-&#x003ba;B in TLR2-mediated inhibition of these genes using RelA<sup>&#x02212;/&#x02212;</sup> macrophages showed that inhibition of CXCL11, but not CIITA, is NF-&#x003ba;B dependent (<xref ref-type="fig" rid="pone-0006329-g006">Fig. 6</xref>). We could not detect binding of p65 or p50 to this site in the CXCL11 promoter (data not shown), suggesting that NF-&#x003ba;B most likely has an indirect inhibitory effect, possibly by inducing expression of a protein that blocks CXCL11 transcription upon TLR2 stimulation. The reversal of transcriptional inhibition seen when new protein synthesis is blocked is concordant with this mechanism (<xref ref-type="fig" rid="pone-0006329-g003">Fig. 3A</xref>).</p><p>We also examined potential epigenetic mechanisms as TLR2 stimulation has been shown to inhibit IFN-&#x003b3;-induced histone acetylation at the promoters of genes involved in MHC class II antigen presentation <xref ref-type="bibr" rid="pone.0006329-Pennini1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0006329-Wang1">&#x0005b;43&#x0005d;</xref>. ChIP experiments done in murine macrophages stimulated with LpqH followed by IFN-&#x003b3; showed that acetylation of histones H3 and H4 was reduced at the CIITA promoter compared to IFN-&#x003b3; stimulation alone <xref ref-type="bibr" rid="pone.0006329-Pennini1">&#x0005b;25&#x0005d;</xref>. This inhibition was abrogated with pharmacological blockade of MAPKs. In addition, this inhibition was partially reversed in the presence of the HDAC inhibitor sodium butyrate, suggesting that inhibition of histone acetylation is one mechanism by which TLR2 stimulation prevents CIITA expression.</p><p>We elaborated on those experiments to determine if inhibition of histone acetylation was a common mechanism for TLR2-mediated inhibition of other IFN-&#x003b3;-inducible genes. In contrast to the inhibition of IFN-&#x003b3;-induced histone acetylation at the CIITA promoter (<xref ref-type="fig" rid="pone-0006329-g005">Fig. 5B and E</xref>), histone acetylation at the CXCL11 promoter was unaffected by TLR2 stimulation (<xref ref-type="fig" rid="pone-0006329-g005">Fig. 5A and D</xref>). Concordant with the transcriptional data, histone acetylation at the NOS2 promoter increased with TLR2 stimulation (<xref ref-type="fig" rid="pone-0006329-g005">Fig. 5C and F</xref>). This indicates that a decrease in modifications that make the chromatin more accessible to transcription factors and coactivators may be involved, but this is not the sole mechanism responsible for TLR2-mediated inhibition of transcriptional responses to IFN-&#x003b3;.</p><p>In contrast to the gene-selective requirement for NF-&#x003ba;B and different effects of TLR2 stimulation on histone acetylation, we found that TLR2 stimulation decreased IFN-&#x003b3;-induced binding of RNA polymerase II at both the CIITA and CXCL11 promoters, but not at the NOS2 promoter (<xref ref-type="fig" rid="pone-0006329-g004">Fig. 4A</xref>). This indicates that while the intermediate signaling steps may vary for distinct genes, TLR2 stimulation interrupts a crucial step in transcription initiation at specific IFN-&#x003b3;-responsive genes.</p><p>In addition to <italic>M. tuberculosis</italic>, other pathogens have developed mechanisms to evade immune responses through disruption of host gene transcription. The intracellular bacteria <italic>Listeria monocytogenes</italic> induces a reduction in total cellular histone acetylation early after infection, mediated partially by listeriolysin O <xref ref-type="bibr" rid="pone.0006329-Hamon1">&#x0005b;60&#x0005d;</xref>. The opportunistic pathogen <italic>Mycobacterium avium</italic> inhibits histone acetylation at the HLA-DR&#x003b1; promoter, possibly through recruitment of HDAC corepressor mSin3a, which was found to bind the promoter following infection <xref ref-type="bibr" rid="pone.0006329-Wang1">&#x0005b;43&#x0005d;</xref>. In those studies, infection also led to a reduction in CBP recruitment to the HLA-DR&#x003b1; promoter.</p><p>Viruses also disrupt host gene transcription by preventing transcriptional machinery assembly at gene promoters. Poliovirus cleaves general transcription factors <xref ref-type="bibr" rid="pone.0006329-Weidman1">&#x0005b;61&#x0005d;</xref>, Rift Valley Fever virus blocks transcription factor assembly <xref ref-type="bibr" rid="pone.0006329-LeMay1">&#x0005b;62&#x0005d;</xref>, and vesicular stomatitis virus targets TBP using an unknown mechanism <xref ref-type="bibr" rid="pone.0006329-Yuan2">&#x0005b;63&#x0005d;</xref>. These all prevent general PolII transcription. However, murine cytomegalovirus has been shown to inhibit specific gene transcription by targeting IFN-&#x003b3;-inducible genes without affecting JAK/STAT activation <xref ref-type="bibr" rid="pone.0006329-Popkin1">&#x0005b;64&#x0005d;</xref>. PolII binding to the promoters of the affected genes was significantly reduced, suggesting that disruption of transcriptional machinery assembly was responsible for this inhibition.</p><p>The findings reported here extend the understanding of the mechanisms that may be used by at least one pathogen, <italic>Mycobacterium tuberculosis</italic>, to evade elimination by adaptive immune responses. Developing the means to increase the efficacy of adaptive immune responses in order to better control infection with <italic>M. tuberculosis</italic> will require additional investigation; increasing the efficacy of IFN-&#x003b3; by restoring macrophage transcriptional responses to this cytokine may be one effective approach, but will require further study.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0006329-Aderem1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aderem</surname><given-names>A</given-names></name><name><surname>Ulevitch</surname><given-names>RJ</given-names></name></person-group><year>2000</year><article-title>Toll-like receptors in the induction of the innate immune response.</article-title><source>Nature</source><volume>406</volume><fpage>782</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">10963608</pub-id></mixed-citation></ref><ref id="pone.0006329-Dunne1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunne</surname><given-names>A</given-names></name><name><surname>O'Neill</surname><given-names>LA</given-names></name></person-group><year>2003</year><article-title>The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense.</article-title><source>Sci STKE</source><volume>2003</volume><fpage>re3</fpage><pub-id pub-id-type="pmid">12606705</pub-id></mixed-citation></ref><ref id="pone.0006329-Foster1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>SL</given-names></name><name><surname>Hargreaves</surname><given-names>DC</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year>2007</year><article-title>Gene-specific control of inflammation by TLR-induced chromatin modifications.</article-title><source>Nature</source><volume>447</volume><fpage>972</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">17538624</pub-id></mixed-citation></ref><ref id="pone.0006329-Lopez1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>M</given-names></name><name><surname>Sly</surname><given-names>LM</given-names></name><name><surname>Luu</surname><given-names>Y</given-names></name><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>H</given-names></name><etal/></person-group><year>2003</year><article-title>The 19-kDa <italic>Mycobacterium tuberculosis</italic> protein induces macrophage apoptosis through Toll-like receptor-2.</article-title><source>J Immunol</source><volume>170</volume><fpage>2409</fpage><lpage>2416</lpage><pub-id pub-id-type="pmid">12594264</pub-id></mixed-citation></ref><ref id="pone.0006329-Mosser1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosser</surname><given-names>DM</given-names></name></person-group><year>2003</year><article-title>The many faces of macrophage activation.</article-title><source>J Leukoc Biol</source><volume>73</volume><fpage>209</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">12554797</pub-id></mixed-citation></ref><ref id="pone.0006329-Mogues1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogues</surname><given-names>T</given-names></name><name><surname>Goodrich</surname><given-names>ME</given-names></name><name><surname>Ryan</surname><given-names>L</given-names></name><name><surname>LaCourse</surname><given-names>R</given-names></name><name><surname>North</surname><given-names>RJ</given-names></name></person-group><year>2001</year><article-title>The relative importance of T cell subsets in immunity and immunopathology of airborne <italic>Mycobacterium tuberculosis</italic> infection in mice.</article-title><source>J Exp Med</source><volume>193</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">11157048</pub-id></mixed-citation></ref><ref id="pone.0006329-Cooper1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>AM</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><name><surname>Griffin</surname><given-names>JP</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name><etal/></person-group><year>1993</year><article-title>Disseminated tuberculosis in interferon gamma gene-disrupted mice.</article-title><source>J Exp Med</source><volume>178</volume><fpage>2243</fpage><lpage>2247</lpage><pub-id pub-id-type="pmid">8245795</pub-id></mixed-citation></ref><ref id="pone.0006329-Flynn1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Triebold</surname><given-names>KJ</given-names></name><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name><etal/></person-group><year>1993</year><article-title>An essential role for interferon gamma in resistance to <italic>Mycobacterium tuberculosis</italic> infection.</article-title><source>J Exp Med</source><volume>178</volume><fpage>2249</fpage><lpage>2254</lpage><pub-id pub-id-type="pmid">7504064</pub-id></mixed-citation></ref><ref id="pone.0006329-Flynn2"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name></person-group><year>2001</year><article-title>Immunology of tuberculosis.</article-title><source>Annu Rev Immunol</source><volume>19</volume><fpage>93</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">11244032</pub-id></mixed-citation></ref><ref id="pone.0006329-Murray1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>HW</given-names></name><name><surname>Granger</surname><given-names>AM</given-names></name><name><surname>Teitelbaum</surname><given-names>RF</given-names></name></person-group><year>1991</year><article-title>Gamma interferon-activated human macrophages and <italic>Toxoplasma gondii, Chlamydia psittaci</italic>, and <italic>Leishmania donovani</italic>: antimicrobial role of limiting intracellular iron.</article-title><source>Infect Immun</source><volume>59</volume><fpage>4684</fpage><lpage>4686</lpage><pub-id pub-id-type="pmid">1937829</pub-id></mixed-citation></ref><ref id="pone.0006329-Murray2"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>HW</given-names></name><name><surname>Rubin</surname><given-names>BY</given-names></name><name><surname>Rothermel</surname><given-names>CD</given-names></name></person-group><year>1983</year><article-title>Killing of intracellular <italic>Leishmania donovani</italic> by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.</article-title><source>J Clin Invest</source><volume>72</volume><fpage>1506</fpage><lpage>1510</lpage><pub-id pub-id-type="pmid">6415111</pub-id></mixed-citation></ref><ref id="pone.0006329-Bhardwaj1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>N</given-names></name><name><surname>Nash</surname><given-names>TW</given-names></name><name><surname>Horwitz</surname><given-names>MA</given-names></name></person-group><year>1986</year><article-title>Interferon-gamma-activated human monocytes inhibit the intracellular multiplication of <italic>Legionella pneumophila</italic>.</article-title><source>J Immunol</source><volume>137</volume><fpage>2662</fpage><lpage>2669</lpage><pub-id pub-id-type="pmid">3093580</pub-id></mixed-citation></ref><ref id="pone.0006329-Skerrett1"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skerrett</surname><given-names>SJ</given-names></name><name><surname>Martin</surname><given-names>TR</given-names></name></person-group><year>1994</year><article-title>Intratracheal interferon-gamma augments pulmonary defenses in experimental legionellosis.</article-title><source>Am J Respir Crit Care Med</source><volume>149</volume><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">8111597</pub-id></mixed-citation></ref><ref id="pone.0006329-Levy1"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Darnell</surname><given-names>JE</given-names><suffix>Jr</suffix></name></person-group><year>2002</year><article-title>Stats: transcriptional control and biological impact.</article-title><source>Nat Rev Mol Cell Biol</source><volume>3</volume><fpage>651</fpage><lpage>662</lpage><pub-id pub-id-type="pmid">12209125</pub-id></mixed-citation></ref><ref id="pone.0006329-Kovarik1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovarik</surname><given-names>P</given-names></name><name><surname>Stoiber</surname><given-names>D</given-names></name><name><surname>Novy</surname><given-names>M</given-names></name><name><surname>Decker</surname><given-names>T</given-names></name></person-group><year>1998</year><article-title>Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation.</article-title><source>Embo J</source><volume>17</volume><fpage>3660</fpage><lpage>3668</lpage><pub-id pub-id-type="pmid">9649436</pub-id></mixed-citation></ref><ref id="pone.0006329-Stoiber1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoiber</surname><given-names>D</given-names></name><name><surname>Kovarik</surname><given-names>P</given-names></name><name><surname>Cohney</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>JA</given-names></name><name><surname>Steinlein</surname><given-names>P</given-names></name><etal/></person-group><year>1999</year><article-title>Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma.</article-title><source>J Immunol</source><volume>163</volume><fpage>2640</fpage><lpage>2647</lpage><pub-id pub-id-type="pmid">10453004</pub-id></mixed-citation></ref><ref id="pone.0006329-Yao1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Kwon</surname><given-names>MJ</given-names></name><name><surname>Matta</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><year>2006</year><article-title>ERK and p38 MAPK signaling pathways negatively regulate CIITA gene expression in dendritic cells and macrophages.</article-title><source>J Immunol</source><volume>177</volume><fpage>70</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">16785500</pub-id></mixed-citation></ref><ref id="pone.0006329-Kincaid1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kincaid</surname><given-names>EZ</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year>2003</year><article-title><italic>Mycobacterium tuberculosis</italic> exerts gene-selective inhibition of transcriptional responses to IFN-gamma without inhibiting STAT1 function.</article-title><source>J Immunol</source><volume>171</volume><fpage>2042</fpage><lpage>2049</lpage><pub-id pub-id-type="pmid">12902509</pub-id></mixed-citation></ref><ref id="pone.0006329-Lafuse1"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafuse</surname><given-names>WP</given-names></name><name><surname>Alvarez</surname><given-names>GR</given-names></name><name><surname>Curry</surname><given-names>HM</given-names></name><name><surname>Zwelling</surname><given-names>BS</given-names></name></person-group><year>2006</year><article-title><italic>Mycobacterium tuberculosis</italic> and <italic>Mycobacterium avium</italic> inhibit IFN- gamma -induced gene expression by TLR2-dependent and independent pathways.</article-title><source>J Interferon Cytokine Res</source><volume>26</volume><fpage>548</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">16881865</pub-id></mixed-citation></ref><ref id="pone.0006329-Pai1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>RK</given-names></name><name><surname>Convery</surname><given-names>M</given-names></name><name><surname>Hamilton</surname><given-names>TA</given-names></name><name><surname>Boom</surname><given-names>WH</given-names></name><name><surname>Harding</surname><given-names>CV</given-names></name></person-group><year>2003</year><article-title>Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from <italic>Mycobacterium tuberculosis</italic>: a potential mechanism for immune evasion.</article-title><source>J Immunol</source><volume>171</volume><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">12816996</pub-id></mixed-citation></ref><ref id="pone.0006329-Pai2"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pai</surname><given-names>RK</given-names></name><name><surname>Pennini</surname><given-names>ME</given-names></name><name><surname>Tobian</surname><given-names>AA</given-names></name><name><surname>Canaday</surname><given-names>DH</given-names></name><name><surname>Boom</surname><given-names>WH</given-names></name><etal/></person-group><year>2004</year><article-title>Prolonged toll-like receptor signaling by <italic>Mycobacterium tuberculosis</italic> and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages.</article-title><source>Infect Immun</source><volume>72</volume><fpage>6603</fpage><lpage>6614</lpage><pub-id pub-id-type="pmid">15501793</pub-id></mixed-citation></ref><ref id="pone.0006329-Ting1"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>LM</given-names></name><name><surname>Kim</surname><given-names>AC</given-names></name><name><surname>Cattamanchi</surname><given-names>A</given-names></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year>1999</year><article-title><italic>Mycobacterium tuberculosis</italic> inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1.</article-title><source>J Immunol</source><volume>163</volume><fpage>3898</fpage><lpage>3906</lpage><pub-id pub-id-type="pmid">10490990</pub-id></mixed-citation></ref><ref id="pone.0006329-Banaiee1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banaiee</surname><given-names>N</given-names></name><name><surname>Kincaid</surname><given-names>EZ</given-names></name><name><surname>Buchwald</surname><given-names>U</given-names></name><name><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name><name><surname>Ernst</surname><given-names>JD</given-names></name></person-group><year>2006</year><article-title>Potent inhibition of macrophage responses to IFN-gamma by live virulent <italic>Mycobacterium tuberculosis</italic> is independent of mature mycobacterial lipoproteins but dependent on TLR2.</article-title><source>J Immunol</source><volume>176</volume><fpage>3019</fpage><lpage>3027</lpage><pub-id pub-id-type="pmid">16493060</pub-id></mixed-citation></ref><ref id="pone.0006329-Fortune1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortune</surname><given-names>SM</given-names></name><name><surname>Solache</surname><given-names>A</given-names></name><name><surname>Jaeger</surname><given-names>A</given-names></name><name><surname>Hill</surname><given-names>PJ</given-names></name><name><surname>Belisle</surname><given-names>JT</given-names></name><etal/></person-group><year>2004</year><article-title><italic>Mycobacterium tuberculosis</italic> inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms.</article-title><source>J Immunol</source><volume>172</volume><fpage>6272</fpage><lpage>6280</lpage><pub-id pub-id-type="pmid">15128816</pub-id></mixed-citation></ref><ref id="pone.0006329-Pennini1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennini</surname><given-names>ME</given-names></name><name><surname>Pai</surname><given-names>RK</given-names></name><name><surname>Schultz</surname><given-names>DC</given-names></name><name><surname>Boom</surname><given-names>WH</given-names></name><name><surname>Harding</surname><given-names>CV</given-names></name></person-group><year>2006</year><article-title><italic>Mycobacterium tuberculosis</italic> 19-kDa lipoprotein inhibits IFN-gamma-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling.</article-title><source>J Immunol</source><volume>176</volume><fpage>4323</fpage><lpage>4330</lpage><pub-id pub-id-type="pmid">16547269</pub-id></mixed-citation></ref><ref id="pone.0006329-Barnes1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PF</given-names></name><name><surname>Mistry</surname><given-names>SD</given-names></name><name><surname>Cooper</surname><given-names>CL</given-names></name><name><surname>Pirmez</surname><given-names>C</given-names></name><name><surname>Rea</surname><given-names>TH</given-names></name><etal/></person-group><year>1989</year><article-title>Compartmentalization of a CD4&#x0002b; T lymphocyte subpopulation in tuberculous pleuritis.</article-title><source>J Immunol</source><volume>142</volume><fpage>1114</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">2464638</pub-id></mixed-citation></ref><ref id="pone.0006329-Gomez1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>JE</given-names></name><name><surname>McKinney</surname><given-names>JD</given-names></name></person-group><year>2004</year><article-title><italic>M. tuberculosis</italic> persistence, latency, and drug tolerance.</article-title><source>Tuberculosis (Edinb)</source><volume>84</volume><fpage>29</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">14670344</pub-id></mixed-citation></ref><ref id="pone.0006329-Kincaid2"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kincaid</surname><given-names>EZ</given-names></name><name><surname>Wolf</surname><given-names>AJ</given-names></name><name><surname>Desvignes</surname><given-names>L</given-names></name><name><surname>Mahapatra</surname><given-names>S</given-names></name><name><surname>Crick</surname><given-names>DC</given-names></name><etal/></person-group><year>2007</year><article-title>Codominance of TLR2-Dependent and TLR2-Independent Modulation of MHC Class II in <italic>Mycobacterium tuberculosis</italic> Infection In Vivo.</article-title><source>J Immunol</source><volume>179</volume><fpage>3187</fpage><lpage>3195</lpage><pub-id pub-id-type="pmid">17709534</pub-id></mixed-citation></ref><ref id="pone.0006329-Jin1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>SE</given-names></name><name><surname>Heo</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>ME</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><etal/></person-group><year>2007</year><article-title>Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide.</article-title><source>Cell</source><volume>130</volume><fpage>1071</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">17889651</pub-id></mixed-citation></ref><ref id="pone.0006329-Steimle1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steimle</surname><given-names>V</given-names></name><name><surname>Siegrist</surname><given-names>CA</given-names></name><name><surname>Mottet</surname><given-names>A</given-names></name><name><surname>Lisowska-Grospierre</surname><given-names>B</given-names></name><name><surname>Mach</surname><given-names>B</given-names></name></person-group><year>1994</year><article-title>Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA.</article-title><source>Science</source><volume>265</volume><fpage>106</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">8016643</pub-id></mixed-citation></ref><ref id="pone.0006329-Pennini2"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennini</surname><given-names>ME</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Croniger</surname><given-names>CM</given-names></name><name><surname>Boom</surname><given-names>WH</given-names></name><etal/></person-group><year>2007</year><article-title>CCAAT/enhancer-binding protein beta and delta binding to CIITA promoters is associated with the inhibition of CIITA expression in response to <italic>Mycobacterium tuberculosis</italic> 19-kDa lipoprotein.</article-title><source>J Immunol</source><volume>179</volume><fpage>6910</fpage><lpage>6918</lpage><pub-id pub-id-type="pmid">17982082</pub-id></mixed-citation></ref><ref id="pone.0006329-Loetscher1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loetscher</surname><given-names>M</given-names></name><name><surname>Gerber</surname><given-names>B</given-names></name><name><surname>Loetscher</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>SA</given-names></name><name><surname>Piali</surname><given-names>L</given-names></name><etal/></person-group><year>1996</year><article-title>Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.</article-title><source>J Exp Med</source><volume>184</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">9064356</pub-id></mixed-citation></ref><ref id="pone.0006329-Cole1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>KE</given-names></name><name><surname>Strick</surname><given-names>CA</given-names></name><name><surname>Paradis</surname><given-names>TJ</given-names></name><name><surname>Ogborne</surname><given-names>KT</given-names></name><name><surname>Loetscher</surname><given-names>M</given-names></name><etal/></person-group><year>1998</year><article-title>Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.</article-title><source>J Exp Med</source><volume>187</volume><fpage>2009</fpage><lpage>2021</lpage><pub-id pub-id-type="pmid">9625760</pub-id></mixed-citation></ref><ref id="pone.0006329-Fuller1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>C</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Reinhart</surname><given-names>TA</given-names></name></person-group><year>2003</year><article-title>In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with <italic>Mycobacterium tuberculosis</italic>.</article-title><source>Infect Immun</source><volume>71</volume><fpage>7023</fpage><lpage>7034</lpage><pub-id pub-id-type="pmid">14638792</pub-id></mixed-citation></ref><ref id="pone.0006329-Sierro1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierro</surname><given-names>F</given-names></name><name><surname>Biben</surname><given-names>C</given-names></name><name><surname>Mart&#x000ed;nez-Mu&#x000f1;oz</surname><given-names>L</given-names></name><name><surname>Mellado</surname><given-names>M</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><etal/></person-group><year>2007</year><article-title>Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7.</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><fpage>14759</fpage><lpage>14764</lpage><pub-id pub-id-type="pmid">17804806</pub-id></mixed-citation></ref><ref id="pone.0006329-Strahl1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strahl</surname><given-names>BD</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year>2000</year><article-title>The language of covalent histone modifications.</article-title><source>Nature</source><volume>403</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">10638745</pub-id></mixed-citation></ref><ref id="pone.0006329-Beg1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><year>1996</year><article-title>An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.</article-title><source>Science</source><volume>274</volume><fpage>782</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">8864118</pub-id></mixed-citation></ref><ref id="pone.0006329-Doi1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>TS</given-names></name><name><surname>Marino</surname><given-names>MW</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Sakakura</surname><given-names>T</given-names></name><etal/></person-group><year>1999</year><article-title>Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality.</article-title><source>Proc Natl Acad Sci U S A</source><volume>96</volume><fpage>2994</fpage><lpage>2999</lpage><pub-id pub-id-type="pmid">10077625</pub-id></mixed-citation></ref><ref id="pone.0006329-Douvas1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douvas</surname><given-names>GS</given-names></name><name><surname>Looker</surname><given-names>DL</given-names></name><name><surname>Vatter</surname><given-names>AE</given-names></name><name><surname>Crowle</surname><given-names>AJ</given-names></name></person-group><year>1985</year><article-title>Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria.</article-title><source>Infect Immun</source><volume>50</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">3930401</pub-id></mixed-citation></ref><ref id="pone.0006329-Rook1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rook</surname><given-names>GA</given-names></name><name><surname>Steele</surname><given-names>J</given-names></name><name><surname>Ainsworth</surname><given-names>M</given-names></name><name><surname>Champion</surname><given-names>BR</given-names></name></person-group><year>1986</year><article-title>Activation of macrophages to inhibit proliferation of <italic>Mycobacterium tuberculosis</italic>: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages.</article-title><source>Immunology</source><volume>59</volume><fpage>333</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">3098676</pub-id></mixed-citation></ref><ref id="pone.0006329-Lee1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Workman</surname><given-names>JL</given-names></name></person-group><year>2007</year><article-title>Histone acetyltransferase complexes: one size doesn't fit all.</article-title><source>Nat Rev Mol Cell Biol</source><volume>8</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">17380162</pub-id></mixed-citation></ref><ref id="pone.0006329-Sengupta1"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>N</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name></person-group><year>2004</year><article-title>Regulation of histone deacetylase activities.</article-title><source>J Cell Biochem</source><volume>93</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">15352162</pub-id></mixed-citation></ref><ref id="pone.0006329-Wang1"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Curry</surname><given-names>HM</given-names></name><name><surname>Zwilling</surname><given-names>BS</given-names></name><name><surname>Lafuse</surname><given-names>WP</given-names></name></person-group><year>2005</year><article-title>Mycobacteria inhibition of IFN-gamma induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells.</article-title><source>J Immunol</source><volume>174</volume><fpage>5687</fpage><lpage>5694</lpage><pub-id pub-id-type="pmid">15843570</pub-id></mixed-citation></ref><ref id="pone.0006329-Zhu1"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Puc</surname><given-names>J</given-names></name><name><surname>Ohgi</surname><given-names>KA</given-names></name><etal/></person-group><year>2007</year><article-title>A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation.</article-title><source>Mol Cell</source><volume>27</volume><fpage>609</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">17707232</pub-id></mixed-citation></ref><ref id="pone.0006329-Pluemsampant1"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pluemsampant</surname><given-names>S</given-names></name><name><surname>Safronova</surname><given-names>OS</given-names></name><name><surname>Nakahama</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>I</given-names></name></person-group><year>2008</year><article-title>Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors.</article-title><source>Int J Cancer</source><volume>122</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">17935135</pub-id></mixed-citation></ref><ref id="pone.0006329-Yang1"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SR</given-names></name><name><surname>Chida</surname><given-names>AS</given-names></name><name><surname>Bauter</surname><given-names>MR</given-names></name><name><surname>Shafiq</surname><given-names>N</given-names></name><name><surname>Seweryniak</surname><given-names>K</given-names></name><etal/></person-group><year>2006</year><article-title>Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages.</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><volume>291</volume><fpage>L46</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16473865</pub-id></mixed-citation></ref><ref id="pone.0006329-Ito1"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Elliot</surname><given-names>WM</given-names></name><name><surname>Cosio</surname><given-names>B</given-names></name><name><surname>Caramori</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>Decreased histone deacetylase activity in chronic obstructive pulmonary disease.</article-title><source>N Engl J Med</source><volume>352</volume><fpage>1967</fpage><lpage>1976</lpage><pub-id pub-id-type="pmid">15888697</pub-id></mixed-citation></ref><ref id="pone.0006329-Hu1"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Fredrickson</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Kirkpatrick</surname><given-names>R</given-names></name><etal/></person-group><year>2000</year><article-title>Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor.</article-title><source>J Biol Chem</source><volume>275</volume><fpage>15254</fpage><lpage>15264</lpage><pub-id pub-id-type="pmid">10748112</pub-id></mixed-citation></ref><ref id="pone.0006329-Lee2"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Rezai-Zadeh</surname><given-names>N</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name></person-group><year>2004</year><article-title>Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A.</article-title><source>Mol Cell Biol</source><volume>24</volume><fpage>765</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">14701748</pub-id></mixed-citation></ref><ref id="pone.0006329-Pflum1"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflum</surname><given-names>MK</given-names></name><name><surname>Tong</surname><given-names>JK</given-names></name><name><surname>Lane</surname><given-names>WS</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name></person-group><year>2001</year><article-title>Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation.</article-title><source>J Biol Chem</source><volume>276</volume><fpage>47733</fpage><lpage>47741</lpage><pub-id pub-id-type="pmid">11602581</pub-id></mixed-citation></ref><ref id="pone.0006329-Tsai1"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SC</given-names></name><name><surname>Seto</surname><given-names>E</given-names></name></person-group><year>2002</year><article-title>Regulation of histone deacetylase 2 by protein kinase CK2.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>31826</fpage><lpage>31833</lpage><pub-id pub-id-type="pmid">12082111</pub-id></mixed-citation></ref><ref id="pone.0006329-Singh1"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>NN</given-names></name><name><surname>Ramji</surname><given-names>DP</given-names></name></person-group><year>2008</year><article-title>Protein kinase CK2, an important regulator of the inflammatory response?</article-title><source>J Mol Med</source><volume>86</volume><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">18437331</pub-id></mixed-citation></ref><ref id="pone.0006329-Kalkhove1"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalkhove</surname><given-names>E</given-names></name></person-group><year>2004</year><article-title>CBP and p300: HATs for different occasions.</article-title><source>Biochem Pharmacol</source><volume>68</volume><fpage>1145</fpage><lpage>1155</lpage><pub-id pub-id-type="pmid">15313412</pub-id></mixed-citation></ref><ref id="pone.0006329-Zhang1"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Vinkemeier</surname><given-names>U</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Chakravarti</surname><given-names>D</given-names></name><name><surname>Horvath</surname><given-names>CM</given-names></name><etal/></person-group><year>1996</year><article-title>Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling.</article-title><source>Proc Natl Acad Sci U S A</source><volume>93</volume><fpage>15092</fpage><lpage>15096</lpage><pub-id pub-id-type="pmid">8986769</pub-id></mixed-citation></ref><ref id="pone.0006329-Huang1"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Ju</surname><given-names>TK</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>CC</given-names></name></person-group><year>2007</year><article-title>Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.</article-title><source>Mol Cell</source><volume>26</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">17434128</pub-id></mixed-citation></ref><ref id="pone.0006329-Yuan1"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>LW</given-names></name><name><surname>Soh</surname><given-names>JW</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><year>2002</year><article-title>Inhibition of histone acetyltransferase function of p300 by PKCdelta.</article-title><source>Biochim Biophys Acta</source><volume>1592</volume><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">12379484</pub-id></mixed-citation></ref><ref id="pone.0006329-Gaston1"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaston</surname><given-names>K</given-names></name><name><surname>Jayaraman</surname><given-names>PS</given-names></name></person-group><year>2003</year><article-title>Transcriptional repression in eukaryotes: repressors and repression mechanisms.</article-title><source>Cell Mol Life Sci</source><volume>60</volume><fpage>721</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">12785719</pub-id></mixed-citation></ref><ref id="pone.0006329-Gupta1"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Kone</surname><given-names>BC</given-names></name></person-group><year>1999</year><article-title>CCAAT/enhancer binding protein-beta trans-activates murine nitric oxide synthase 2 gene in an MTAL cell line.</article-title><source>Am J Physiol</source><volume>276</volume><fpage>F599</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">10198420</pub-id></mixed-citation></ref><ref id="pone.0006329-Litvak1"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Litvak</surname><given-names>V</given-names></name><name><surname>Ramsey</surname><given-names>SA</given-names></name><name><surname>Rust</surname><given-names>AG</given-names></name><name><surname>Zak</surname><given-names>DE</given-names></name><name><surname>Kennedy</surname><given-names>KA</given-names></name><etal/></person-group><year>2009</year><article-title>Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals.</article-title><source>Nat Immunol</source><volume>10</volume><fpage>437</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">19270711</pub-id></mixed-citation></ref><ref id="pone.0006329-Hamon1"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamon</surname><given-names>MA</given-names></name><name><surname>Batsche</surname><given-names>E</given-names></name><name><surname>Regnault</surname><given-names>B</given-names></name><name><surname>Tham</surname><given-names>TN</given-names></name><name><surname>Seveau</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>Histone modifications induced by a family of bacterial toxins.</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><fpage>13467</fpage><lpage>13472</lpage><pub-id pub-id-type="pmid">17675409</pub-id></mixed-citation></ref><ref id="pone.0006329-Weidman1"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidman</surname><given-names>MK</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name><name><surname>Kundu</surname><given-names>P</given-names></name><name><surname>Tsai</surname><given-names>W</given-names></name><etal/></person-group><year>2003</year><article-title>The interaction of cytoplasmic RNA viruses with the nucleus.</article-title><source>Virus Res</source><volume>95</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">12921997</pub-id></mixed-citation></ref><ref id="pone.0006329-LeMay1"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le May</surname><given-names>N</given-names></name><name><surname>Dubaele</surname><given-names>S</given-names></name><name><surname>Proietti De Santis</surname><given-names>L</given-names></name><name><surname>Billecocq</surname><given-names>A</given-names></name><name><surname>Bouloy</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus.</article-title><source>Cell</source><volume>116</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">14980221</pub-id></mixed-citation></ref><ref id="pone.0006329-Yuan2"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Yoza</surname><given-names>BK</given-names></name><name><surname>Lyles</surname><given-names>DS</given-names></name></person-group><year>1998</year><article-title>Inhibition of host RNA polymerase II-dependent transcription by vesicular stomatitis virus results from inactivation of TFIID.</article-title><source>Virology</source><volume>251</volume><fpage>383</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">9837802</pub-id></mixed-citation></ref><ref id="pone.0006329-Popkin1"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popkin</surname><given-names>DL</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Karaskov</surname><given-names>E</given-names></name><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Bremner</surname><given-names>R</given-names></name><etal/></person-group><year>2003</year><article-title>Murine cytomegalovirus paralyzes macrophages by blocking IFN gamma-induced promoter assembly.</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><fpage>14309</fpage><lpage>14314</lpage><pub-id pub-id-type="pmid">14614150</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>These studies were supported by a grant from the National Institute of Health (RAI046097). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>